The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Subscribe To Our Newsletter & Stay Updated
